Near infrared photoimmunotherapy targeting the cutaneous lymphocyte antigen for mycosis fungoides

Silic-Benussi, Micol; Saponeri, Andrea; Michelotto, Anna; Russo, Irene; Colombo, Anna; Pelizzo, Maria Guglielmina; Ciminale, Vincenzo; Alaibac, Mauro

doi:10.1080/14712598.2021.1858791

Cited by 8 publications

(7 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…So far, the impact of HECA-452 on CTCL cell survival has not been reported except after the combination of the mAb to a photoabsorber dye, the hydrophilic phtalocyanine IRdye 700DX (IR700), actionable by near-infrared light (Silic-Benussi et al, 2021). No direct effect of HECA-452 on CTCL survival was observed, which might be due to the use of a lower concentration of antibody than in our study.…”

Section: Discussioncontrasting

confidence: 65%

See 1 more Smart Citation

Cutaneous Lymphocyte Antigen Is a Potential Therapeutic Target in Cutaneous T-Cell Lymphoma

Peru

Prochazkova-Carlotti

Cherrier

et al. 2022

Journal of Investigative Dermatology

View full text Add to dashboard Cite

Section: Discussioncontrasting

confidence: 65%

“…More recently, CLA was selected to be specifically targeted by a light-sensitive molecule on MF cells (Silic-Benussi et al, 2021). Therefore, we decided to investigate the expression of CLA in both patients' circulating SCs and MF cell line.…”

Section: Introductionmentioning

confidence: 99%

Cutaneous Lymphocyte Antigen Is a Potential Therapeutic Target in Cutaneous T-Cell Lymphoma

Peru

Prochazkova-Carlotti

Cherrier

et al. 2022

Journal of Investigative Dermatology

View full text Add to dashboard Cite

“…The efficacy of NIR‐PIT has been demonstrated in various tumor models both in vitro and in vivo. In an in vitro study of mycosis fungoides (MF), which is a type of low‐grade T‐cell lymphoma, cutaneous lymphocyte antigen (CLA) is targeted by an anti‐CLA antibody conjugated with IR700, which successfully induced substantial increase in MF cell death 63 . Loss of viability of cells upon NIR irradiation was observed in this study.…”

Section: Nir‐pit Targeting Tumor Biomarkers In Animal Modelsmentioning

confidence: 79%

Quickly evolving near‐infrared photoimmunotherapy provides multifaceted approach to modern cancer treatment

Monaco

Yokomizo

Choi

et al. 2021

VIEW

View full text Add to dashboard Cite

Among modalities of cancer immunotherapy, near-infrared photoimmunotherapy (NIR-PIT) has reached significant preclinical and clinical stages and quickly evolved over the last 5 years. NIR-PIT uses deep-penetrable NIR light to induce physicochemical changes in the antibody-photosensitizer conjugate (APC), leading to resultant necrosis and immunogenic cell death (ICD) of the cancer cells. Alternatively, other types of photomedicine use photosensitizers to convert absorbed light energy either into reactive oxygen species for photodynamic therapy (PDT) or into heat for photothermal therapy (PTT). ICD is a unique and relevant outcome of NIR-PIT because it induces long-lasting antitumor host immunity, which overcomes the immunosuppressive network of cancer. Due to its high specificity and durable antitumor effects, NIR-PIT is now considered a promising cancer therapy, and optimized NIR-PIT is readily expanding its applicability to many different types of cancer. Along with the traditional method of NIR-PIT, new avenues in its realm of treatment are currently being explored, such as the targeting of other immunosuppressive elements, delivery of NIR light through a catheter, real-time imaging for tumor detection, and the use of tumor-seeking small molecules for improved efficacy and safety. In addition, its effect on hyperpermeability has opened a door for a wide array of combination therapies with other modalities. This review summarizes the recent findings in clinical and preclinical studies of NIR-induced photomedicine and its future significance in the field of cancer research.

show abstract

“…Few therapies are available for MF treatment; therefore, new therapeutic approaches are necessary. A study by Silic-Benussi et al investigated anti-cutaneous lymphocyte antigen (CLA)-targeted NIR-PIT, which effectively destroyed MF-derived My-La CD4 + cells in vitro 161 .…”

Section: Potential Application Of Nir-pit For Cancer Treatmentmentioning

confidence: 99%

Near-infrared photoimmunotherapy: design and potential applications for cancer treatment and beyond

Wei¹,

Qi²,

Hamblin³

et al. 2022

Theranostics

View full text Add to dashboard Cite

Near-infrared photoimmunotherapy (NIR-PIT) is a newly developed cancer treatment modality based on a target-specific photosensitizer conjugate (TSPC) composed of an NIR phthalocyanine photosensitizer and an antigen-specific recognition system. NIR-PIT has predominantly been used for targeted therapy of tumors via local irradiation with NIR light, following binding of TSPC to antigen-expressing cells. Physical stress-induced membrane damage is thought to be a major mechanism underlying NIR-PIT-triggered photokilling. Notably, NIR-PIT can rapidly induce immunogenic cell death and activate the adaptive immune response, thereby enabling its combination with immune checkpoint inhibitors. Furthermore, NIR-PIT-triggered “super-enhanced permeability and retention” effects can enhance drug delivery into tumors. Supported by its potential efficacy and safety, NIR-PIT is a rapidly developing therapeutic option for various cancers. Hence, this review seeks to provide an update on the (i) broad range of target molecules suitable for NIR-PIT, (ii) various types of receptor-selective ligands for designing the TSPC “magic bullet,” (iii) NIR light parameters, and (iv) strategies for enhancing the efficacy of NIR-PIT. Moreover, we review the potential application of NIR-PIT, including the specific design and efficacy in 19 different cancer types, and its clinical studies. Finally, we summarize possible NIR-PIT applications in noncancerous conditions, including infection, pain, itching, metabolic disease, autoimmune disease, and tissue engineering.

show abstract

Near infrared photoimmunotherapy targeting the cutaneous lymphocyte antigen for mycosis fungoides

Cited by 8 publications

References 22 publications

Cutaneous Lymphocyte Antigen Is a Potential Therapeutic Target in Cutaneous T-Cell Lymphoma

Cutaneous Lymphocyte Antigen Is a Potential Therapeutic Target in Cutaneous T-Cell Lymphoma

Quickly evolving near‐infrared photoimmunotherapy provides multifaceted approach to modern cancer treatment

Near-infrared photoimmunotherapy: design and potential applications for cancer treatment and beyond

Contact Info

Product

Resources

About